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Bone metabolism appears to inﬂuence insulin secretion and sensitivity, and insulin promotes bone formation in
animals, but similar evidence in humans is limited. The objectives of this study are to explore if bone turnover
markerswere associatedwith insulin secretion and sensitivity and to determine if bone turnovermarkers predict
changes in insulin secretion and sensitivity. The study population encompassed 576 non-diabetic adultmenwith
normal glucose tolerance (NGT; n=503) or impaired glucose regulation (IGR; n=73). Baselinemarkers of bone
resorption (CTX) and formation (P1NP) were determined in the fasting state and after a 2-h hyperinsulinaemic,
euglycaemic clamp. An intravenous glucose tolerance test (IVGTT) and a 2-h oral glucose tolerance test (OGTT)
were performed at baseline, and theOGTTwas repeated after 3 years. Therewere nodifferences in bone turnover
marker levels between NGT and IGR. CTX and P1NP levels decreased by 8.0% (p b 0.001) and 1.9% (p b 0.01) be-
tween baseline and steady-state during the clamp. Fasting plasma glucosewas inversely associatedwith CTX and
P1NP both before and after adjustment for recruitment centre, age, BMI, smoking and physical activity. However,
baseline bone turnover markers were neither associated with insulin sensitivity (assessed using
hyperinsulinaemic euglycaemic clamp and OGTT) nor with insulin secretion capacity (based on IVGTT and
OGTT) at baseline or at follow-up. Although inverse associations between fasting glucose and markers of bone
turnover were identiﬁed, this study cannot support an association between insulin secretion and sensitivity in
healthy, non-diabetic men.
© 2017 Published by Elsevier Inc.
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1. Introduction
Fracture risk is increased in people with type 2 diabetes (T2D) de-
spite bonemass generally being normal or increased [1]. Clinical studies
revealed decreased levels of circulating biochemical markers of bone
formation and resorption in individuals with T2D [1] as well as lower
bone formation and resorption and lower bone quality in bone biopsies
in T2D [2]. Themechanisms behind these changes in bone turnover and
the increased risk of fracture in T2D are not fully elucidated.
Inadequate secretion of insulin and insulin resistance are the corner-
stones in the development of T2D. Insulin is considered bone anabolic
due to stimulatory effects on osteoblast differentiation [3], and mice not
expressing the insulin receptor in osteoblasts have low bonemass [4]. In-
sulin signaling in osteoblasts favours osteoclast bone resorption activity
through secretion of osteoprotegerin and, subsequently, generation and
release of the undercarboxylated form of osteocalcin, an osteoblast-
secreted marker of bone formation, which may stimulate insulin secre-
tion from the pancreatic β-cells [5]. Furthermore, hyperglycaemia im-
pairs osteoblast activity and survival [6–8] and promotes adipogenic
rather than osteogenic differentiation of adipose and muscle-derived
stem cells [9]. Additionally, gain-and-loss-of-function models of insulin
signaling in mice osteoblasts provide evidence that a high fat diet causes
insulin resistance in bone, which lowers bone turnover and osteocalcin
activity, causing higher bone volume and glucose intolerance in mice
[10].
Thus, based on preclinical investigations, insulin levels and beta-cell
function as well as insulin sensitivity would be expected to correlate
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with markers of bone formation in humans, but clinical data from non-
diabetic individuals remain to be established. Integration of bone and
glucose homeostasis in humans is supported by direct associations be-
tween total osteocalcin and estimates of insulin secretion and sensitivi-
ty based on oral and intravenous glucose tolerance tests (OGTT or
IVGTT) [11–14] and inverse associations with plasma glucose in T2D
[15], age-related increases in plasma glucose [13], and incidence of
T2D [16–18]. Also, markers of bone resorption but not bone formation
were inversely associated with the incidence of T2D [17]. However,
other investigations have not provided support of associations between
total osteocalcin and plasma glucose or incident diabetes [19–22]. Al-
though the increased levels of fasting insulin usually observed in early
stages of T2D could promote bone formation and subsequently bone re-
sorption due to coupling of bone formation and resorption, possibly
explaining the association between bone mineral density (BMD) and
fasting insulin levels observed in some [23,24] but not all epidemiolog-
ical studies of non-diabetic individuals [25], insulin resistance in bone
cells may reduce bone formation and resorption, which are reported
to be lower in patients with T2D [1,26]. Corroborating these reports, in-
sulin sensitivity assessed by an IVGTT was inversely associated with
BMD in a selected group of non-diabetic, generally obese men with
heart disease [27], and homeostasis model assessment of insulin
resistance (HOMA-IR) was positively associated with volumetric BMD
in postmenopausal, non-diabetic women [28]. While these studies sug-
gest that insulin resistance may increase bone mass, possibly due to
lower bone turnover in T2D [26], it remains unknown if insulin sensitiv-
ity measured using the gold standard, i.e. the hyperinsulinaemic,
euglycaemic clamp and insulin secretion assessed by OGGT or IVGTT,
are associated with bone turnover in non-diabetic individuals.
The aim of this study was to investigate the relationship between
bone turnover using markers of bone resorption (CTX) and formation
(P1NP), and insulin secretion and sensitivity assessed with the
hyperinsulinaemic euglycaemic clamp and measures derived from in-
travenous and oral glucose tolerance tests in clinically healthy, non-
diabetic men. Furthermore, we explored if bone turnover was associat-
ed with insulin secretion and 3-year changes in insulin secretion and
sensitivity.
2. Materials and methods
The Relationship between Insulin Sensitivity and Cardiovascular
Risk Study (RISC) is a prospective cohort study conducted at 19
European research centres across 14 European countries [29]. Baseline
and 3-year follow-up data were included in the present study. In
short, between 2002 and 2004, 1556 clinically healthy female and
male volunteers aged 29–61 years were recruited from the local com-
munity. Individuals being treated for obesity, diabetes, hypertension
or lipid disorders were excluded from participation. The exclusion
criteria comprised recent weight change (N5 kg) or major surgery,
chronic pulmonary and cardiovascular diseases, renal failure including
renal transplant, seizure disorders including epilepsy, steroid treatment,
and any diagnosis of cancer in the previous 5 years but not osteoporosis
or treatment for osteoporosis. After physical examination, biochemical
testing and a 75-g 2-hOGTTwere performed. Individualswith increased
fasting or 2-h glucose levels (≥7 and 11.1 mmol/L, respectively), in-
creased blood pressure (≥140/90 mmHg) or increased lipids (triglycer-
ide ≥4.6 mmol/l and total cholesterol ≥7.8 mmol/L) were excluded [29].
In order to limit the effects of factors known or anticipated to inﬂuence
bone and glucose homeostasis such as menstrual cycle, only male par-
ticipants of the RISC study were selected for the present investigation.
2.1. Anthropometrics and lifestyle
Body height was measured using a standard ruler (stadiometer)
without shoes. Waist size was measured on bare skin at the smallest
point between costal edges and the iliac crest. Body weight and fat
free mass (FFM) were measured with participants in light clothes and
in the fasting state using a Tanita bioimpedence TBF-300 body composi-
tion analyser (Tanita International, United Kingdom). Physical activity
was registered by the 7-day International Physical Activity Question-
naire (IPAQ) and used to calculate metabolic equivalent energy expen-
diture per week. The level of physical activity was explored both as a
continuous and a categorical measure as the study population was
categorized in three groups based on their level of physical activity (in-
active, minimally active and health enhancing physical activity).
Smoking status was dichotomized according to whether the participant
reported current use of tobacco products.
2.2. Assessment of glucose homeostasis
All participants underwent a 75-g OGTT after an overnight fast, with
samples being collected at after 0, 30, 60, 90 and 120 min, at baseline
and at 3 years. At baseline, hyperinsulinaemic euglycaemic clamp was
performed within one week of the OGTT. During the clamp, insulin
was infused at a rate of 240 pmol permin per squaremeter, and infusion
of dextrose (20%) was modiﬁed at 5–10 min intervals in order to keep
plasma glucose levels within 0.8mmol/L of 4.5–5.5mmol/L. To evaluate
ﬁrst phase insulin secretion, an intravenous glucose tolerance test
(IVGTT) was performed after the clamp in a subset of the participants
(n = 438 men). A weight-adjusted dose of glucose (0.3 g per kg
bodyweight)was infused in oneminute, and sampleswere subsequent-
ly collected after 2, 4, 6 and 8 min.
2.3. Biochemical tests
Blood samples were separated into serum and plasma and stored at
−80 degrees until biochemical tests were performed. Samples were
transferred on dry ice between sites and laboratories. Glucosewasmea-
sured using the glucose oxidase technique (Cobas Integra, Roche)
(within- and between assay coefﬁcients of variation: 1.8% and 2.1%).
Serum insulin and C-peptide were assessed using a two-sided time-
resolved ﬂouroimmunoassay (AutoDELFIA, Insulin Kit, Wallac Oy,
Turku, Finland) based on monoclonal antibodies (Within and between
assay coefﬁcients of variation: Insulin (normal levels): 4.3% and 3.7%.
C-peptide (normal levels): 5.3% and 2.6%). Serum Procollagen type I
amino-terminal propeptide (PINP) and C-telopeptide of type I collagen
(CTX-1) were measured by the chemiluminescence method in the
fasting state and at steady-state of a euglycaemia during the clamp
(IDS-iSYS. Within and between assay coefﬁcients of variation (CV):
PINP: 7% and 7%. CTX-1: 5% and 18%). VitaminDwasmeasured using di-
rect competitive electrochemiluminescence immunoassay (COBAS 311,
Roche).
2.4. Insulin sensitivity and beta-cell function
Based on the OGTT, participants were classiﬁed into two groups, in-
dividualswith normal glucose tolerance (NGT) or impaired glucose reg-
ulation (IGR), which included individuals with impaired fasting
glycaemia (6.1–6.9mmol/l), impaired glucose tolerance (2-h-OGTT glu-
cose levels between 7.8 and 11.0mmol/l) and a combination of both. In-
sulin sensitivity was calculated as the ratio of the average glucose
infusion rate during the last 40 min of the 2-h clamp (adjusted for fat-
free mass), M, and mean insulin levels during the same time interval
(M/I). At both baseline and the 3-year follow-up, insulin sensitivity
was assessed using plasma glucose and insulin levels measured during
the 2-h-OGTT at baseline and follow-up.We used the oral glucose insu-
lin sensitivity index normalized to lean body mass optimized for the
RISC-study (OGIS-RISC),whichhas been shown to correlatewith insulin
sensitivity assessed by clamp [30]. Insulin resistance was also assessed
using homeostatic model assessment (Fasting plasma glucose – fasting
plasma insulin divided by 22.5).
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Beta-cell function was assessed as the total insulin secretion during
the OGTT (ISRtot) and beta-cell glucose sensitivity (GluSens), which re-
ﬂects the response to changes in glucose levels. Furthermore, the ratio
between the incremental insulin secretions assessed using C-peptide
and plasma glucose concentration in the ﬁrst 8 min after the intrave-
nous glucose bolus were used to determine the acute insulin response
(AIR) during IVGTT.
3. Statistics
Data are presented as percentages, and as mean (±standard devia-
tion) or median (interquartile range) as appropriate. First, the study
population was stratiﬁed into two groups according to the glycaemic
status, NGT or IGR. Second, differences in baseline anthropometrics as
well as measurements of fasting and insulin-stimulated levels of bone
turnover markers and glucose homeostasis between individuals with
NGT or IGR were investigated using Student's t-test, Mann-Whitney's
test and Chi-square tests. Third, the associations between bone turnover
markers andmeasures of insulin sensitivity and secretionwere assessed
using Lowess-plots and regression analyses. For the regression analyses,
three different regression models were used: 1) adjusted for recruit-
ment centre 2) further adjustment for age and BMI 3) further adjust-
ment for smoking and physical activity (measured as a continuous
variable) for the entire study population, and then for the normal glu-
cose tolerance and the impaired glucose regulation groups. Skewed var-
iableswere log transformedprior to performing the regression analyses,
whichwere performedwith the available data andwithout imputations
as data were assumed to bemissing at random. These regression analy-
ses were performed for the complete study population as no interaction
between glycaemic statuses was observed. The regression models were
repeated with adjustment for 25-OHD levels (continuous measure) or
after restriction of the analyses to participants with normal levels of
25-OHD as well as used to test if baseline bone turnover markers pre-
dicted changes in fasting plasma glucose, 2-h glucose and measures of
insulin sensitivity and secretion. Fourth, changes in bone turnover
markers during the clampwere evaluated using Student's t-test (paired
data). Signiﬁcance was accepted at p b 0.05.
Calculations were performed using STATA, v. 14 (StataCorp, College
Station, Tx, US).
4. Results
4.1. Baseline anthropometrics and life style factors
Characteristics of the study population are presented in Table 1.
None of the participants were treated with corticosteroids or anti-
resorptive drugs. Among the 576 non-diabetic men, 503 (87%) had
NGT and 73 IGR. Age, body weight and BMI were higher in individuals
with IGR (Table 1). Neither physical activity nor tobacco use differed be-
tween individuals with NGT and IGR (Table 1).
4.2. Glucose homeostasis
Insulin sensitivity assessed from the OGTT (OGIS-RISC) or from the
hyperinsulinaemic euglycaemic clamp (M/I) was higher and HOMA-IR
lower in individuals with NGT (Table 2). Participants with NGT had
lower ISRtot and higher GluSens during the OGTT than those with IGR
(Table 2), while no difference in AIR during the IVGTTwas observed be-
tween these groups.
The OGTT was repeated in 468 of the 576 (73%) participants after
three years. Fasting plasma glucose (+0.2 mmol/L, p b 0.001) and
fasting serum insulin (+2 pmol/L, p b 0.01) were slightly increased
after 3-years follow-up. Moreover, ISRtot was increased (+2 pmol/L, p
b 0.001), insulin sensitivity assessed by OGIS-RISC was reduced (−0.3
μmol/min/KgFFM, p b 0.01), and HOMA-IR was increased (+0.6, p b
0.001) after three years (Table 2). Signiﬁcant changes in these outcomes
at follow-up were observed only in individuals with NGT, possibly due
to lower number of individuals with IGR (Table 2).
4.3. Bone turnover markers
No differences in fasting levels of CTX and P1NP were observed be-
tween individuals with NGT and IGR (Table 1). After 120 min of insulin
stimulation (during the clamp), CTX and P1NP levels had decreased by
8.0% (p b 0.001) and 1.9% (p b 0.01), respectively (Fig. 1). Decreases in
both CTX and P1NPduring insulin stimulationwere observed in individ-
uals with NGT, whereas only CTX decreased signiﬁcantly in individuals
with IGR (Table 1). Vitamin D was measured in 77% (n = 451) of the
participants. Vitamin D deﬁciency deﬁned as a serum 25-OHD below
20 ng/dl was observed in 47% (n = 211) of the study population, and
the prevalence of vitamin D deﬁciency was comparable in individuals
with NGT and IGR (Table 1).
4.4. Relationship between bone turnover and glucose homeostasis
Both CTX and P1NP were inversely associated with fasting plasma
glucose in the study population before and after adjustment for poten-
tial confounders, but these relationswere not reﬂected in an association
between bone turnover markers and fasting levels of serum insulin
(Table 3).
The relationships between bone turnover markers and measures of
insulin sensitivity (OGIS-RISC and Log-M/I) as well estimates of insulin
secretion during IVGTT (AIR) and OGTT (ISRtot and GluSens) were ﬁrst
explored using Lowess plots (Supplementary material, a–f) but none
of these plots pointed towards associations.
Table 1
Basic anthropometrics, life style factors and bone turnovermarkers inmen. The EGIR-RISC
Study.
All
n = 576
NGT
n = 503
IGR
n = 73
p-Value (comparison of glycaemic
groups)
Anthropometrics
Age
(years)
42
(36–49)
42
(36–49)
47
(39–51)
0.028
BMI
(kg/m2)
26.2
(3.5)
26.1
(3.4)
27.9
(3.4)
b0.001
Smokers
(%)
28% 28% 32% 0.717
Physical activity n = 503 n = 482 n = 69
Physical activity
1: inactive 1: 21% 20% 26%
2: minimally active 2: 42% 42% 42%
3: health enhancing
activities
Data available in 551
individuals
3: 37% 38% 32% b0.001
METS per week 2300
(960–4668)
2253
(990–4746)
2475
(735–4158)
0.465
Vitamin D levels n = 445 n = 397 n = 48
Vitamin D (ng/dL) 21.1 (10.2) 21.3 (10.2) 20.0
(10.0)
0.413
Vitamin D deﬁciency %
25-OHD b20 ng/dL
47% 46% 58% 0.109
Bone turnover markers
Fasting serum CTX (μg/L) 466 (172) 468 (170) 461 (194) 0.719
Fasting serum P1NP (μg/L) 49 (17) 49 (17) 48 (18) 0.629
Insulin-stimulated serum CTX
(μg/L)
428
(157)§§§
430
(157)§§§
418 (156) 0.546
Insulin-stimulated serum P1NP
(μg/L)
48 (17)§§ 48 (17)§§ 47 (17) 0.541
Comparison of bone turnover markers at baseline and at 3-years: §p b 0.05, §§p b 0.01 and
§§§p b 0.001.
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Nevertheless, insulin sensitivity determined by OGIS-RISC was di-
rectly associated with both bone turnover markers in the complete
study population. However, the association disappeared after inclusion
of age and BMI in the regression models (Table 3). Neither of the bone
turnover markers was associated with hyperinsulinaemic euglycaemic
clamp-based measurements of insulin sensitivity (M/I) in unadjusted
models. Insulin resistance assessed using the HOMA-IR was inversely
associated with both CTX and P1NP in unadjusted analyses and
remained inversely associated with P1NP but not CTX in the fully ad-
justed models. While insulin secretion during the IVGTT (AIR) was not
associated with bone turnover markers either before or after adjust-
ments, ISRtot during the OGTT was inversely associated with levels of
P1NP in unadjusted but not adjusted models (Table 3).
As vitamin D deﬁciency could interfere with the assessment of a rela-
tionship between bone turnover markers and glucose homeostasis, re-
gression analyses were repeated with adjustments for vitamin D levels
(as a continuous variable) and in participants that were vitamin D replete
(25-OHD ≥ 20 ng/dL), however, neither of the results of the regression
analyses changed noticeably after these adjustments (data not shown).
4.5. Bone turnover markers and changes in insulin sensitivity and secretion
Baseline levels of neither P1NP nor CTX were associated with in-
creases in fasting plasma glucose levels during follow-up (Table 4). Base-
line levels of CTX and P1NP were not associated with changes in fasting
serum insulin levels, ISRtot, OGIS-RISC, or HOMA-IR during follow-up
(Table 4).
5. Discussion
The primary aim of this study was to investigate if bone turnover and
insulin secretion and sensitivity are integrated in humans as expected,
based on previous animal studies.We expected that levels of bone forma-
tion and resorption markers would be directly associated with insulin
Table 2
Glucose homeostasis at baseline and at 3-years of follow-up in men. The EGIR-RISC Study.
All
n = 576
NGT
n = 503
IGR
n = 73
p-Value (comparison of glycaemic groups)
Glucose homeostasis at baseline
Fasting plasma glucose (mmol/L) 5.2 (0.5) 5.2 (0.5) 5.7 (0.6) b0.001
120 min plasma glucose (mmol/L) 5.7 (1.4) 5.4 (1.1) 7.6 (1.5) b0.001
Fasting serum insulin (pmol/L) 32 (22–47) 31 (21–45) 47 (33–67) b0.001
120 min serum insulin (pmol/L) 131 (75–230) 122 (68–210) 286 (160–509) b0.001
Total insulin secretion (OGTT) 41 (15) 40 (14) 50 (17) b0.001
GluSens (pmol/min/m2 mM) 102.3 (74.2–139.1) 107 (78–142) 78 (57–102) b0.001
OGIS-RISC (μmol/min/kg FFM) 10.2 (1.9) 10.4 (1.8) 8.3 (1.4) b0.001
HOMA-IR 1.4 (0.8–1.9) 1.4 (0.8–1.8) 2.1 (1.3–2.7) b0.001
M/I (μmol/kg FFM/min/nmol/L) 111.9 (81.4–151.5) 116 (85–156) 86 (62–126) b0.001
n = 438 n = 380 n = 58
AIR (pmol/L) (IVGTT) 790 (486–1133) 802 (501–1152) 701 (414–1002) 0.112
Glucose homeostasis at follow-up
n = 461 n = 413 n = 48
Fasting plasma glucose (mmol/L) 5.4 (0.6)§§§ 5.3 (0.6)§§§ 5.6 (0.6) b0.001
Fasting serum insulin (pmol/L) 33 (24–49)§§ 33 (23–47)§§§ 39 (27–59) 0.093
Total insulin secretion (OGTT) 43 (15)§§§ 42 (15)§§§ 46 (18) 0.179
HOMA-IR 1.6 (0.9–2.0)§§§ 1.6 (0.9–1.9)§§§ 1.9 (1.1–2.5) 0.027
OGIS-RISC (μmol/min/kg FFM) 9.9 (2.1)§§ 10.1 (2.1)§§§ 9.0 (1.9) 0.001
GluSens (pmol/min/m2 mM) 107 (78–140) 109 (85–149) 74 (59–87) b0.001
Comparison of glucose homeostasis at baseline and at 3-years: §p b 0.05, §§p b 0.01 and §§§p b 0.001.
Fig. 1. Bone turnover markers measured in the fasting state and after insulin stimulation (120 min) during a hyperinsulinaemic euglycaemic clamp in 567 non-diabetic adult men (ALL)
with normal glucose tolerance (NGT; n = 503) or impaired glucose regulation (IGR; n = 73). Data are mean (standard deviation). §§§p b 0.001 and §§p b 0.01 versus fasting.
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secretion, but neither of the bone turnovermarkers investigatedwere as-
sociated with insulin secretion capacity assessed using the IVGTT and the
OGTT. Equally, we did not observe any relation between bone turnover
markers and insulin sensitivity assessed using OGTT and the gold-
standard method, i.e. hyperinsulinaemic euglycaemic clamp. Therefore,
these results demonstrate that bone turnover assessed using bone turn-
over markers and peripheral insulin sensitivity and insulin secretion are
unrelated in healthy, non-diabetic men.
Our observations are not in complete alignment with previous inves-
tigations. An inverse association between bone formation assessed using
P1NP and insulin sensitivity determined using an IVGTT and a direct asso-
ciation between P1NP and insulin resistance based on HOMA-IR was
observed in 63men andwomenwithNGT or IFG [31].Whilewe detected
an inverse relation between P1NP and insulin sensitivity based on
hyperinsulinaemic euglycaemic clamp in individualswith IGR, the associ-
ation was only present after adjustments. These differences in observa-
tions may be explained by skeletal muscle or hepatic insulin resistance
that leads to fasting hyperinsulinaemia, which promotes bone formation,
or insulin resistance in bone, that impairs bone turnover. Furthermore, an
inverse association between insulin resistance determined using HOMA-
IR and bone resorption (CTX) but not formation (P1NP) was detected in
2955 elderly men, but neither of these bone turnover markers was asso-
ciatedwith insulin resistance after adjustment for age, BMI and comorbid-
ities [17]. Further, P1NP was directly associated with insulin resistance
Table 3
Regression coefﬁcients (95% conﬁdence intervals) between bone turnovermarkers andmeasures of glucose homeostasis at baseline, according to glucose tolerance status. B The EGIR-RISC
Study.
CTX (ng/L) P1NP (ng/L)
All p-Value All p-Value
Adjusted for centre
Fasting plasma glucose (mmol/L) −53.7 (−81.9;−25.4) b0.001 −5.1 (−7.9;−2.3) b0.001
Fasting serum insulin (pmol/L) −0.4 (−1.1; 0.3) 0.280 −0.1 (−0.1; 0.0) 0.082
Log AIR (pmol/L) 15.7 (−6.5; 37.8) 0.165 1.1 (−1.1; 3.2) 0.326
Total insulin secretion (OGTT) −0.2 (−1.3; 0.7) 0.570 −0.1 (−0.2;−0.1) 0.017
Log GluSens (pmol/min/m2 mM) 16.8 (−8.6; 42.2) 0.195 0.7 (−1.8; 3.3) 0.571
Log M/I (μmol/kg FFM/min/nmol/L) 2.7 (−24.9; 30.4) 0.845 1.4 (−1.3; 4.2) 0.306
OGIS-RISC (μmol/min/kg FFM) 12.4 (4.9; 19.9) 0.001 1.0 (0.3; 1.8) 0.007
Log HOMA-IR −36.3 (−61.3;−11.3) 0.004 −3.6 (−6.1;−1.1) 0.005
Adjusted for age, BMI and centre
Fasting plasma glucose (mmol/L) −36.9 (−65.5;−8.3) 0.011 −3.2 (−6.0;−0.4) 0.028
Fasting serum insulin (pmol/L) 0.5 (−0.3; 1.3) 0.198 0.0 (−0.1; 0.1) 0.702
Log AIR (pmol/L) 17.9 (−4.2; 40.1) 0.112 0.9 (−1.2; 3.1) 0.400
Total insulin secretion (OGTT) 0.7 (−0.3; 1.7) 0.180 −0.0 (−0.1; 0.1) 0.524
Log GluSens (pmol/min/m2 mM) 12.2 (−12.7; 37.1) 0.335 0.2 (−2.3; 2.6) 0.889
Log M/I (μmol/kg FFM/min/nmol/L) −36.1 (−66.6;−5.6) 0.020 −1.9 (−4.9; 1.2) 0.225
OGIS-RISC (μmol/min/kg FFM) 3.9 (−4.9; 12.6) 0.384 0.1 (−0.8; 1.0) 0.824
Log HOMA-IR −9.4 (−37.8; 19.1) 0.518 −1.0 (−3.9; 1.8) 0.474
Adjusted for age, BMI, smoking, physical activity and centre
Fasting plasma glucose (mmol/L) −49.1 (−86.3;−11.9) 0.010 −5.8 (−9.7;−1.9) 0.004
Fasting serum insulin (pmol/L) −0.1 (−1.2; 1.0) 0.801 −0.1 (−2.9; 2.8) 0.955
Log AIR (pmol/L) 11.6 (−16.1; 39.3) 0.410 −0.1 (−0.2; 0.1) 0.327
Total insulin secretion (OGTT) 0.2 (−0.2; 1.6) 0.817 −0.1 (−0.2; 0.1) 0.220
Log GluSens (pmol/min/m2 mM) 5.7 (−26.5; 37.9) 0.729 −0.7 (−4.1; 2.7) 0.674
Log M/I (μmol/kg FFM/min/nmol/L) −27.5 (−65.7; 10.7) 0.158 −1.7 (−5.8; 2.3) 0.392
OGIS-RISC (μmol/min/kg FFM) 5.2 (−5.6; 16.1) 0.345 0.4 (−0.8; 1.5) 0.506
Log HOMA-IR −31.2 (−69.0; 6.5) 0.104 −4.1 (−8.1;−0.1) 0.043
Table 4
Change inper cent frombaseline ofmeasures of glucose homeostasis and regression coefﬁcients (95% conﬁdence intervals) between baseline bone turnovermarker levels and delta values
of measures of glucose homeostasis. The EGIR-RISC Study.
Δ Fasting plasma
glucose
(mmol/L)
Δ Fasting serum insulin
(pmol/L)
Δ Total insulin
secretion
(OGTT)
Δ GluSens
(pmol/min/m2 mM)
Δ OGIS
(μmol/min/kg FFM)
Δ HOMA-IR
n = 468 n = 439 n = 415 n = 415 n = 398 n = 437
% change from
baseline
+2.9% +8.4% +6.8% +1.5% −3.0% +11.2%
Bone turnover markers
CTX (μg/L)# 0.002 (−0.001; 0.001) 0.001 (−0.011; 0.011) −0.003 (−0.009;
0.004)
−0.012 (−0.051;
0.027)
−0.001 (−0.001;
0.001)
0.001 (−0.001; 0.001)
P1NP (μg/L)# −0.001 (−0.004;
0.002)
−0.022 (−0.126;
0.823)
−0.012 (−0.076;
0.053)
0.122 (−0.267; 0.511) 0.005 (−0.004; 0.014) −0.001 (−0.006;
0.003)
Adjusted for centre, age, BMI, smoker and physical activity
CTX (μg/L)## 0.001 (0.000; 0.001)⁎ −0.003 (−0.015;
0.009)
−0.001 (−0.008;
0.005)
−0.001 (−0.050;
0.031)
−0.001 (−0.001;
0.001)
−0.001 (−0.001;
0.001)
P1NP (μg/L)## 0.001 (−0.003;
0.003)⁎⁎
−0.038 (−0.150;
0.075)
−0.004 (−0.072;
0.064)
0.197 (−0.199; 0.593) 0.003 (−0.006; 0.013) −0.001 (−0.006;
0.003)
# Adjusted for recruitment centre.
## Adjusted for centre, age, BMI, smoker, IPAQMETS.
⁎ p b 0.05.
⁎⁎ p b 0.01.
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assessed on the basis of HOMA-IR in 1010 Swedishmen aged 70–81 years
prior to but not after adjustment for osteocalcin levels, suggesting that
osteocalcin but not P1NP is independently associated with glucose ho-
meostasis [32]. In addition, urinary NTX, a bone resorption marker, was
not associated with fasting plasma glucose, whereas the level of
osteocalcin was inversely associated with fasting plasma glucose in 380
elderlymen [13]. Jointly, these previous investigations do not consistently
support an association between BMTs such as P1NP and CTX and glucose
homeostasis. In light of the results of the present investigation, which re-
lies on measurements of insulin sensitivity assessed on the basis of both
OGTTandhyperinsulinaemic euglycaemic clamp, evidence of an indepen-
dent relationship between bone turnover markers and insulin sensitivity
or indeed secretion is limited.
By contrast, levels of osteocalcin appear to represent more than just
bone formation. Accordingly, undercarboxylated osteocalcin and total
osteocalcin are inversely associatedwith fasting plasma glucose and insu-
lin resistance and directly associated with insulin sensitivity in humans
investigated using OGTT and hyperinsulinaemic euglycaemic clamp [13,
15,32,33,35]. These results emphasize that undercarboxylated osteocalcin
and osteocalcin may reﬂect functions beyond that of bone remodeling.
Furthermore, osteocalcin and undercarboxylated osteocalcin may predict
changes in glucose levels or development of T2D according to some [13,
16,17,36] but not all prospective investigations [20–22]. Osteocalcin was
not measured in the present investigation as osteocalcin is sensitivity to
degradation, prompting blood samples for osteocalcin measurements to
be chilled at 4 degrees Celsius immediately after being collected, which
was not part of the protocol in our investigation [37]. Furthermore, assays
that measure bioactive osteocalcin, i.e. osteocalcin decarboxylated specif-
ically at residue Glu17, are unavailable in humans [38]. The potential inte-
gration of bone and glucose homeostasis in humans needs to be assessed
using other biochemical markers that may not portray the physiological
effects of alterations in levels of bioactive osteocalcin during bone remod-
eling. Rather than assessing osteocalcin, we investigated the ability of
commonly used bone turnover markers to predict alterations in glucose
homeostasis during a short follow-up period. In keeping with the cross-
sectional data, bone turnover markers were not associated with changes
in insulin sensitivity or insulin secretion after 3-years follow-up; suggest-
ing that bone turnover per se and glucose homeostasis are unrelated in
healthy men.
The majority of previous clinical investigations have reported lower
levels of bone turnover markers in individuals with type 1 or 2 diabetes
than in controls [26]. Therefore, in order to investigate the relationship
between bone turnover markers and glucose, insulin sensitivity and se-
cretion independently of overt hyperglycaemia, patients with any type
of diabetes were excluded from the present study. Although most of
the study participants were glucose tolerant, a considerable number of
participants had an abnormal glucose regulation. However, bone turn-
over markers were similar in those classiﬁed as either NGT or IGR sug-
gesting that they may remain normal at least until development of
overt hyperglycaemia.
Investigation of the impact of long-term fasting hyperinsulinaemia
without concurrent hyperglycaemia in human poses obvious difﬁcul-
ties. The acute effect of insulin on bone turnover has been investigated
in a limited number of clinical studies by using hyperinsulinaemic
euglycaemic clamps that involved different rates and durations of insu-
lin infusion, i.e. 40 mU/m2 per min, 80 mU/m2 per min or 0.5 mU/kg
total bodyweight permin. Exposure to these levels of insulin had no ap-
parent imminent effect on bone turnover assessed using bone turnover
markers [39–41]. By contrast, a reduced bone resorption has been re-
ported in hyperinsulinaemic euglycaemic clamps thatwere either of ex-
tended duration (40 mU/m2 per min; 4 h), and hyperinsulinaemic
hypoglycaemic clamps (80 mU/m2 per min; BG reduced to 2.5 nM)
[39,41]. Importantly, these investigations included relatively small
study populations that differed with regard to age, body composition
and presence of T2D. Notably, the design of the clamp applied in the
study by Basu et al. [40] that included 7 individuals with T2D and 7
controls relied on a different study design as secretion of pancreatic hor-
mones during the clamp was prevented by infusion of somatostatin,
growth hormone and glucagon, and insulin was infused at three differ-
ent rates in order to imitate the physiological range of insulin.While the
investigators detected an association between levels of CTX and insulin
sensitivity, after adjustment for BMI, the relationship was no longer sig-
niﬁcant, indicating that bone turnover and insulin sensitivity assessed
during the clamp with control for potentially confounding secretions
of pancreatic hormones known to inﬂuence glucose homeostasis and
bone metabolism are distinct. However, while bone turnover markers
seemingly remain fairly unchanged by insulin at physiological levels
during a euglycaemic clamp, Clowes et al. [41] observed a substantial re-
duction in bone turnover markers during a hypoglycaemic clamp per-
formed using similar levels of insulin, possibly explained according to
the investigators by inhibitory effects of hypoglycaemia on bone cells,
hormones counteracting hyperglycaemia or reductions in PTH levels
observed during the hypoglycaemia.
We observed decreases in the level of CTX and minor reductions in
P1NP levels during a 2-h hyperinsulinaemic euglycaemic clamp, which
by design was similar to some of the studies that reported steady levels
of bone turnover markers during insulin exposure. This disagreement
maybe explainedby several factors includingdifferences in the character-
istics of the study population as the present investigation included sub-
stantially more individuals and was restricted to non-diabetic men,
whichmay have reduced the variation, allowing us to identify alterations
in bone turnover markers levels during insulin exposure. The overall ef-
fect of insulin on bone cell activity remains uncertain [42]. The decrease
in P1NP and CTX during the clamp could be explained by several factors,
including reduced levels of hormones known to promote bone activity
such as IGF-1 or IGF-1 binding proteins, alterations in clearance of the
bone turnover markers or inhibitory effects on osteoclasts activity,
which leads to decreased osteoblast activity. CTX did not decrease in par-
ticipants with IGR, but similar numerical changes in CTX levels were ob-
served before and after insulin-stimulation, indicating that the
discrepancy in CTX levels in the response to insulin stimulation between
NGT and IGR could be explained by lower power. Importantly,
hyperinsulinaemic euglycaemic clamps relies on physiological insulin
levels that are sustained beyond that observed in normal physiology;
therefore, these changes in bone turnover markers may not represent
the effects of physiological levels of insulin on bone turnover. Further-
more, the observed reductions in bone turnover markers are markedly
smaller than those observed during consumption of food [43], suggesting
that the overall acute effect of intravenously administered insulin on bone
turnover is minor.
Several factors need consideration when the results of the present
investigation are to be interpreted. We cannot exclude the possibility
that the relationships between bone turnover markers and insulin se-
cretion and sensitivity differ in individuals with manifest diabetes or
in women. Furthermore, although adjustment for 25-OHD levels or re-
striction of the investigations to those that were vitamin D replete ap-
peared not to change the results, it could be argued that the
relationship between bone turnover markers and glucose homeostasis
may vary between those with low and normal levels of vitamin D. Be-
cause BMDwas not measured, we were unable to assess if the relation-
ship between bone turnover markers and glucose homeostasis differed
between individuals with high or low bone mass. Finally, although the
size of the study population provided sufﬁcient power to investigate
the main aims, i.e. the relationships between bone turnover markers
and insulin sensitivity and secretion, several comparisons without si-
multaneous adjustment for multiple testing were performed, which in-
variably increases the risk of spurious ﬁndings.
6. Conclusions
The present investigation showed that levels of commonly used bio-
chemical markers of bone formation and resorption are not associated
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with insulin sensitivity and secretion assessed by use of different tests
including hyperinsulinaemic euglycaemic clamp, IVGTT and OGTT in a
very large study population of carefully characterized, non-diabetic
men. Additionally, we did not observe any relationship between base-
line bone turnover markers and 3-year changes in insulin sensitivity
and secretion. Jointly, these results do not support the notion that
bone turnover and glucose homeostasis are integrated in adult men.
When possible, it needs to be investigated if levels of bioactive
osteocalcin are associated with glucose homeostasis in adult non-
diabetic individuals.
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